Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
about
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.Selumetinib for the treatment of non-small cell lung cancer.Current Landscape of Targeted Therapy in Lung Cancer.Understanding and targeting resistance mechanisms in NSCLC.MEK inhibitors under development for treatment of non-small-cell lung cancer.SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer.Current Development Status of MEK Inhibitors.An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Aqueous extract of Sapindus mukorossi induced cell death of A549 cells and exhibited antitumor property in vivo.Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer.MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.No room for statins in the quest for survival benefits in small cell lung cancer.A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Inhibition of MEK, a canonical KRAS pathway effector in mutant NSCLCPrecision oncology: separating the wheat from the chaffIn the literature: August 2018Personalized therapy for lung cancer: Striking a moving targetPalbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in -mutant non-small cell lung cancer
P2860
Q38621231-1B9CF84C-7227-4BB8-9B3F-B594F22A6BE7Q38663069-7ADD001C-BFAB-4B9B-879E-2C17E3989850Q46034707-5544B9B1-1FC8-4BFE-965F-B248416BBB8DQ46915997-02951222-E8CB-4C98-BC9F-73BDA2510AAAQ47318847-3F3ECE71-F510-437C-89E4-8FA7C4F45302Q47432675-6FF43CBB-E52B-4D61-A62D-17B7EEA23E16Q47712403-1C95CD64-20A7-4891-B32D-8F3D62EF1439Q47735535-177CDA74-C6BB-48D8-8BFB-653C4BB015C3Q48179589-90A2626B-CEDB-4AC2-92E9-72838F12FBC3Q48190445-A364C77E-9F6E-40EC-8B79-3EF203DA2260Q49887897-FB1AF318-2114-4EED-8F6B-26C3FE7B1839Q52647921-DD2AE3A8-FCA4-49CB-A06B-EDF14B9968F5Q52719185-C943C976-E040-428A-A02B-27D5752E54F6Q53705974-F01B872E-3F5B-44ED-BE75-51ED0E8DFB83Q54109659-9E79C2AC-BF8F-4DD8-8597-CD179B7E77B7Q54949177-DE7C1ECF-4270-4D91-94F7-3CDEC1A97681Q54978327-434D6BAD-2DFA-4417-98B5-0C230E019DF9Q55062496-537C69DF-69BA-4527-BC74-77DC2DDDDE6DQ55339149-E6B6FB52-1176-4576-958C-0B8ADBF0B0B7Q55515297-97CF2281-CB5E-40D1-9C76-010599F02892Q58562568-C5EFE5EF-AD2B-498E-91FF-D3CF9608D581Q58698377-B7B9545B-E1CF-4869-A969-17450DC1E387Q58780159-27BC0A74-F36D-4EEB-93AF-42A822778B33Q58792324-38570571-8C4C-4E0C-8F04-4598A6554A07Q58801080-554478F8-D4B0-4213-AE3B-E15A434E2476
P2860
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Selumetinib Plus Docetaxel Com ...... T-1 Randomized Clinical Trial.
@en
type
label
Selumetinib Plus Docetaxel Com ...... T-1 Randomized Clinical Trial.
@en
prefLabel
Selumetinib Plus Docetaxel Com ...... T-1 Randomized Clinical Trial.
@en
P2093
P2860
P356
P1476
Selumetinib Plus Docetaxel Com ...... T-1 Randomized Clinical Trial.
@en
P2093
Alexander Kohlmann
Artem Poltoratskiy
Dana Ghiorghiu
David J Carlile
David Lawrence
Elaine Kilgour
Fabrice Barlesi
Gabriella Mariani
Johan Vansteenkiste
Juergen Wolf
P2860
P304
P356
10.1001/JAMA.2017.3438
P407
P577
2017-05-01T00:00:00Z